{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063540","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.753494+00:00","generated_at":"2026-05-22T18:12:28.784945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026","bullets":["Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).","R&D expenses $24.6M for Q1 2025, up from $22.0M YoY due to pipeline advancement and higher personnel costs.","Registrational plan for ORIC-944 in mCRPC: first Phase 3 trial targeted for 1H 2026; ORIC-114 Phase 3 in 1L NSCLC expected later in 2026.","Entered clinical trial collaboration with Johnson & Johnson for ORIC-114 plus subcutaneous amivantamab in 1L EGFR exon 20 NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063540","json":"https://secwatch.observer/filing/0000950170-25-063540.json","markdown":"https://secwatch.observer/filing/0000950170-25-063540.md","text":"https://secwatch.observer/filing/0000950170-25-063540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025063540/0000950170-25-063540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025063540/oric-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T18:12:28.784945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}